Pegcrisantaspase

Drug Profile

Pegcrisantaspase

Alternative Names: Asparec; JZP-416; mPEG-R-crisantaspase; PEG-crisantaspase; Pegylated-crisantaspase; PEGylated-Erwinia-chrysanthemi-L-asparaginase; Polyethylene-glycol-Erwinia-chrisanthemi-L-asparaginase

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Alize Pharma
  • Developer EUSA Pharma; Jazz Pharmaceuticals Inc
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Acute lymphoblastic leukaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in France (IV, Infusion)
  • 06 Jan 2016 Jazz Pharmaceuticals terminates phase II trial in Acute Lymphoblastic Leukemia in USA (NCT02257684)
  • 02 Mar 2015 Jazz Pharmaceuticals suspends enrolment in a phase II/III trial for Acute lymphoblastic leukaemia (Second-line therapy or greater, In adolescents, In children, In infants) in USA (NCT02257684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top